表紙:ハンター症候群治療の中東・アフリカ市場-業界動向と2028年までの予測
市場調査レポート
商品コード
1029933

ハンター症候群治療の中東・アフリカ市場-業界動向と2028年までの予測

Middle East and Africa Hunter Syndrome Treatment Market- Industry Trends and Forecast to 2028

出版日: | 発行: Data Bridge Market Research Private Limited | ページ情報: 英文 100 Pages | 納期: 3-5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.50円
ハンター症候群治療の中東・アフリカ市場-業界動向と2028年までの予測
出版日: 2021年08月01日
発行: Data Bridge Market Research Private Limited
ページ情報: 英文 100 Pages
納期: 3-5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中東・アフリカのハンター症候群治療市場規模は、2021年から2028年にかけて、7.0%のCAGRで成長すると予測されています。

当レポートでは、中東・アフリカのハンター症候群治療市場について調査分析し、新たな治療法、規制ガイドライン(MPS II)、促進要因、抑制要因、市場機会、COVID-19の影響、重症度別、タイプ別、合併症別、エンドユーザー別、流通チャネル別、地域別市場情報、企業情勢、SWOT分析、企業プロファイルを提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 ハンター症候群の新たな治療法

  • 治療:DNL310
  • 治療:JR141
  • 治療:TAK-609/SHP609/HGT-2310
  • 治療:RGX-121
  • 治療:SB-913
  • 治療:AVR-RD-05
  • 治療:ODIPARCIL
  • 治療:AGT-181
  • 治療:EGT-301

第6章 ハンター症候群の規制ガイドライン(MPS II)

  • ハンター症候群:米国の規制の枠組み
  • ハンター症候群:欧州の規制の枠組み
  • ハンター症候群:アジア太平洋地域の規制の枠組み

第7章 疫学

第8章 市場概要

  • 促進要因
    • ハンター症候群の有病率の増加
    • 遺伝子治療の採用の高まり
    • 政府のイニシアチブの増加
    • 公的および民間企業の資金の増加
    • 技術の進歩
  • 抑制要因
    • 現在の治療の副作用
    • MPSII治療開発のための厳格な政府規制
    • ハンター症候群の存在について人々の間の認知不足
    • MPSIIの治療に関連する高コスト
  • 市場機会
    • 疾患特有の治療への高い需要
    • 主要企業の間でのコラボレーション、および合併と買収
    • 新規ルートの薬の存在
  • 課題
    • 現在の治療の限界
  • 不適切な償還方針

第9章 中東・アフリカのハンター症候群治療市場:COVID-19の影響

  • 価格への影響
  • 需要への影響
  • サプライチェーンへの影響
  • 製造業者のための戦略的決定
  • 結論

第10章 中東・アフリカのハンター症候群治療市場:重症度別

  • 概要
  • 中等度から重度
  • 軽度から中等度

第11章 中東・アフリカのハンター症候群治療市場:タイプ別

  • 概要
  • 酵素補充療法
    • ELAPRASE+TAK-609
    • ハンテラーゼ
    • IZCARGO
  • 幹細胞移植
    • 臍帯移植
    • 骨髄移植
  • 外科的治療
    • 心臓弁置換術
    • 気管切開術
    • 気道陽圧装置
    • 共同拘縮
    • 腹部ヘルニア手術
    • その他
  • その他

第12章 中東・アフリカのハンター症候群治療市場:合併症別

  • 概要
  • 呼吸器疾患
  • 神経性障害
  • 心血管
  • 筋骨格
  • 胃腸障害
  • 眼科
  • 聴能学
  • 歯科
  • その他

第13章 中東・アフリカハンター症候群治療市場:エンドユーザー別

  • 概要
  • 病院
  • クリニック
  • ヘルスケア
  • その他

第14章 中東・アフリカハンター症候群治療市場:流通チャネル別

  • 概要
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第15章 中東・アフリカハンター症候群治療市場:地域別

  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • エジプト
    • イスラエル
    • クウェート
    • その他中東およびアフリカの残りの部分

第16章 中東・アフリカのハンター症候群治療市場:企業情勢

  • 企業シェア分析:中東・アフリカ

第17章 SWOT分析

第18章 企業プロファイル

  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • GREEN CROSS CORP.
  • ABBOTT
  • AVROBIO, INC.
  • BD
  • CANBRIDGE LIFE SCIENCES LTD.
  • DENALI THERAPEUTICS
  • HOMOLOGY MEDICINES, INC.
  • INVENTIVA
  • JASPER THERAPEUTICS, INC.
  • JCR PHARMACEUTICALS CO., LTD.
  • JOHNSON & JOHNSONS SERVICES, INC.
  • MEDTRONIC
  • NOVARTIS AG
  • ON-X LIFE TECHNOLOGIES(A SUBSIDIARY OF CRYOLIFE, INC.)
  • PFIZER INC.
  • REGENXBIO INC.
  • SANGAMO THERAPEUTICS
  • STRYKER
  • UCB S.A.

第19章 アンケート

第20章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 2 MIDDLE EAST AND AFRICA MODERATE TO SEVERE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 3 MIDDLE EAST AND AFRICA MILD TO MODERATE IN MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 4 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 5 MIDDLE EAST AND AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 6 MIDDLE EAST AND AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 7 MIDDLE EAST AND AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 8 MIDDLE EAST AND AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 9 MIDDLE EAST AND AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 10 MIDDLE EAST AND AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 11 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 12 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 13 MIDDLE EAST AND AFRICA RESPIRATORY DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 14 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 15 MIDDLE EAST AND AFRICA CARDIOVASCULAR IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 16 MIDDLE EAST AND AFRICA MUSCULOSKELETAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 17 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISORDERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 18 MIDDLE EAST AND AFRICA OPHTHALMIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 19 MIDDLE EAST AND AFRICA AUDIOLOGIC IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 20 MIDDLE EAST AND AFRICA DENTAL IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 21 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 22 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
  • TABLE 23 MIDDLE EAST AND AFRICA HOSPITALS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 24 MIDDLE EAST AND AFRICA CLINICS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 25 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 26 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 27 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
  • TABLE 28 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 29 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN HUNTER SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 30 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 31 MIDDLE EAST AND AFRICA OTHERS IN HUNTER SYNDROME TREATMENT MARKET, BY REGION, 2019-2028 (USD MILLION)
  • TABLE 32 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
  • TABLE 33 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 34 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 35 MIDDLE EAST & AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 36 MIDDLE EAST & AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 37 MIDDLE EAST & AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 38 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 39 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 40 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 41 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 42 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 43 SOUTH AFRICA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 44 SOUTH AFRICA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 45 SOUTH AFRICA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 46 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 47 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 48 SOUTH AFRICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 49 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 50 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 51 SAUDI ARABIA ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 52 SAUDI ARABIA STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 53 SAUDI ARABIA SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 54 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 55 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 56 SAUDI ARABIA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 57 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 58 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 59 U.A.E. ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 60 U.A.E. STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 61 U.A.E. SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 62 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 63 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 64 U.A.E. HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 65 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 66 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 67 EGYPT ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 68 EGYPT STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 69 EGYPT SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 70 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 71 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 72 EGYPT HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 73 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 74 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 75 ISRAEL ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 76 ISRAEL STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 77 ISRAEL SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 78 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 79 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 80 ISRAEL HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 81 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)
  • TABLE 82 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 83 KUWAIT ENZYME REPLACEMENT THERAPY (ERT) IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 84 KUWAIT STEM CELL TRANSPLANT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 85 KUWAIT SURGICAL TREATMENT IN HUNTER SYNDROME TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
  • TABLE 86 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS, 2019-2028 (USD MILLION)
  • TABLE 87 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY END USER, 2019-2028 (USD MILLION)
  • TABLE 88 KUWAIT HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
  • TABLE 89 REST OF MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY, 2019-2028 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
  • FIGURE 2 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : DATA TRIANGULATION
  • FIGURE 3 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : DROC ANALYSIS
  • FIGURE 4 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : COMPANY RESEARCH ANALYSIS
  • FIGURE 6 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : INTERVIEW DEMOGRAPHICS
  • FIGURE 7 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : DBMR MARKET POSITION GRID
  • FIGURE 8 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : MARKET END USER COVERAGE GRID
  • FIGURE 9 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : VENDOR SHARE ANALYSIS
  • FIGURE 10 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET : SEGMENTATION
  • FIGURE 11 INCREASING PREVALANCE OF HUNTER SYNDROME IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 12 MODERATE TO SEVERE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET IN 2021 & 2028
  • FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET FOR HUNTER SYNDROME TREATMENT PRODUCT MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028
  • FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET
  • FIGURE 16 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY, 2020
  • FIGURE 19 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY END USER, 2020
  • FIGURE 20 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
  • FIGURE 21 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: SNAPSHOT (2020)
  • FIGURE 22 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020)
  • FIGURE 23 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2021 & 2028)
  • FIGURE 24 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY COUNTRY (2020 & 2028)
  • FIGURE 25 MIDDLE EAST & AFRICA HUNTER SYNDROME TREATMENT MARKET: BY SEVERITY (2021-2028)
  • FIGURE 26 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: COMPANY SHARE 2020 (%)
目次

Middle East and Africa hunter syndrome treatment market is projected to register a healthy CAGR of 7.0% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028.

Market Segmentation:

Middle East and Africa Hunter Syndrome Treatment Market, By Severity (Mild to Moderate, Moderate to Severe), Type (Enzyme Replacement Therapy (ERT), Stem Cell Transplant, Surgical Treatment, Others), Complications (Respiratory Disorders, Neurological Disorders, Gastrointestinal Disorders, Cardiovascular, Ophthalmic, Audiologic, Dental, Musculoskeletal, Others), End User (Hospitals, Clinics, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Some of the major factors contributing to the growth of hunter syndrome treatment market are:

  • Increasing prevalence of hunter syndrome
  • Rising adoption of gene therapy
  • Increasing government initiatives
  • Increasing fund by public and private organizations

Market Players:

The key market players for Middle East and Africa hunter syndrome treatment market are listed below:

  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Medtronic
  • Abbott
  • BD
  • Novartis AG
  • Stryker

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 SEVERITY LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET END USER COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 EMERGING TREATMENTS FOR HUNTER SYNDROME

  • 5.1 TREATMENT: DNL310
  • 5.2 TREATMENT: JR141
  • 5.3 TREATMENT: TAK-609/SHP609/HGT-2310
  • 5.4 TREATMENT: RGX-121
  • 5.5 TREATMENT: SB-913
  • 5.6 TREATMENT: AVR-RD-05
  • 5.7 TREATMENT: ODIPARCIL
  • 5.8 TREATMENT: AGT-181
  • 5.9 TREATMENT: EGT-301

6 REGULATORY GUIDELINES FOR HUNTER SYNDROME (MPS II)

  • 6.1 U.S REGULATORY FRAMEWORK FOR HUNTER SYNDROME
  • 6.2 EUROPE REGULATORY FRAMEWORK FOR HUNTER SYNDROME
  • 6.3 ASIA-PACIFIC REGULATORY FRAMEWORK FOR HUNTER SYNDROME

7 EPIDEMIOLOGY

8 MARKET OVERVIEW

  • 8.1 DRIVERS
    • 8.1.1 INCREASING PREVALENCE OF HUNTER SYNDROME
    • 8.1.2 RISING ADOPTION OF GENE THERAPY
    • 8.1.3 INCREASING GOVERNMENT INITIATIVES
    • 8.1.4 INCREASING FUND BY PUBLIC AND PRIVATE ORGANISATIONS
    • 8.1.5 TECHNOLOGICAL ADVANCEMENTS
  • 8.2 RESTRAINTS
    • 8.2.1 ADVERSE EFFECTS OF CURRENT TREATMENTS
    • 8.2.2 STRINGENT GOVERNMENT REGULATIONS FOR MPS II TREATMENT DEVELOPMENT
    • 8.2.3 UNAWARENESS AMONG PEOPLE OF THE EXISTENCE OF HUNTER SYNDROME
    • 8.2.4 HIGH COST ASSOCIATED WITH TREATMENT OF MPS II
  • 8.3 OPPORTUNITIES
    • 8.3.1 HIGH DEMAND OF DISEASE-SPECIFIC TREATMENT
    • 8.3.2 RISING COLLABORATIONS, AND MERGERS & ACQUISITIONS AMONG THE MARKET PLAYERS
    • 8.3.3 PRESENCE OF NOVEL PIPELINE DRUGS
  • 8.4 CHALLENGES
    • 8.4.1 LIMITATIONS OF CURRENT TREATMENT
  • 8.5 IMPROPER REIMBURSEMENT POLICIES

9 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET

  • 9.1 IMPACT ON PRICE
  • 9.2 IMPACT ON DEMAND
  • 9.3 IMPACT ON SUPPLY CHAIN
  • 9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
  • 9.5 CONCLUSION

10 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY SEVERITY

  • 10.1 OVERVIEW
  • 10.2 MODERATE TO SEVERE
  • 10.3 MILD TO MODERATE

11 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY TYPE

  • 11.1 OVERVIEW
  • 11.2 ENZYME REPLACEMENT THERAPY
    • 11.2.1 ELAPRASE + TAK-609
    • 11.2.2 HUNTERASE
    • 11.2.3 IZCARGO
  • 11.3 STEM CELL TRANSPLANT
    • 11.3.1 UMBILICAL CORD TRANSPLANT
    • 11.3.2 BONE MARROW TRANSPLANT
  • 11.4 SURGICAL TREATMENT
    • 11.4.1 CARDIAC VALVE REPLACEMENT SURGERY
    • 11.4.2 TRACHEOSTOMY
    • 11.4.3 POSITIVE AIRWAY PRESSURE DEVICES
    • 11.4.4 JOINT CONTRACTURES
    • 11.4.5 ABDOMINAL HERNIA SURGERY
    • 11.4.6 OTHERS
  • 11.5 OTHERS

12 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY COMPLICATIONS

  • 12.1 OVERVIEW
  • 12.2 RESPIRATORY DISORDERS
  • 12.3 NEUROLOGICAL DISORDERS
  • 12.4 CARDIOVASCULAR
  • 12.5 MUSCULOSKELETAL
  • 12.6 GASTROINTESTINAL DISORDERS
  • 12.7 OPHTHALMIC
  • 12.8 AUDIOLOGIC
  • 12.9 DENTAL
  • 12.10 OTHERS

13 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY END USER

  • 13.1 OVERVIEW
  • 13.2 HOSPITALS
  • 13.3 CLINICS
  • 13.4 HOME HEALTHCARE
  • 13.5 OTHERS

14 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 14.1 OVERVIEW
  • 14.2 HOSPITAL PHARMACY
  • 14.3 RETAIL PHARMACY
  • 14.4 ONLINE PHARMACY
  • 14.5 OTHERS

15 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET, BY REGION

  • 15.1 MIDDLE EAST & AFRICA
    • 15.1.1 SOUTH AFRICA
    • 15.1.2 SAUDI ARABIA
    • 15.1.3 U.A.E.
    • 15.1.4 EGYPT
    • 15.1.5 ISRAEL
    • 15.1.6 KUWAIT
    • 15.1.7 REST OF MIDDLE EAST & AFRICA

16 MIDDLE EAST AND AFRICA HUNTER SYNDROME TREATMENT MARKET: COMPANY LANDSCAPE

  • 16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

17 SWOT ANALYSIS

18 COMPANY PROFILE

  • 18.1 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 18.1.1 COMPANY SNAPSHOT
    • 18.1.2 REVENUE ANALYSIS
    • 18.1.3 COMPANY SHARE ANALYSIS
    • 18.1.4 PRODUCT PORTFOLIO
    • 18.1.5 RECENT DEVELOPMENTS
  • 18.2 GREEN CROSS CORP.
    • 18.2.1 COMPANY SNAPSHOT
    • 18.2.2 REVENUE ANALYSIS
    • 18.2.3 COMPANY SHARE ANALYSIS
    • 18.2.4 PRODUCT PORTFOLIO
    • 18.2.5 RECENT DEVELOPMENT
  • 18.3 ABBOTT
    • 18.3.1 COMPANY SNAPSHOT
    • 18.3.2 REVENUE ANALYSIS
    • 18.3.3 PRODUCT PORTFOLIO
    • 18.3.4 RECENT DEVELOPMENTS
  • 18.4 AVROBIO, INC.
    • 18.4.1 COMPANY SNAPSHOT
    • 18.4.2 PRODUCT PORTFOLIO
    • 18.4.3 RECENT DEVELOPMENTS
  • 18.5 BD
    • 18.5.1 COMPANY SNAPSHOT
    • 18.5.2 REVENUE ANALYSIS
    • 18.5.3 PRODUCT PORTFOLIO
    • 18.5.4 RECENT DEVELOPMENT
  • 18.6 CANBRIDGE LIFE SCIENCES LTD.
    • 18.6.1 COMPANY SNAPSHOT
    • 18.6.2 PRODUCT PORTFOLIO
    • 18.6.3 RECENT DEVELOPMENTS
  • 18.7 DENALI THERAPEUTICS
    • 18.7.1 COMPANY SNAPSHOT
    • 18.7.2 REVENUE ANALYSIS
    • 18.7.3 PRODUCT PORTFOLIO
    • 18.7.4 RECENT DEVELOPMENTS
  • 18.8 HOMOLOGY MEDICINES, INC.
    • 18.8.1 COMPANY SNAPSHOT
    • 18.8.2 REVENUE ANALYSIS
    • 18.8.3 TECHNOLOGY PORTFOLIO
    • 18.8.4 RECENT DEVELOPMENTS
  • 18.9 INVENTIVA
    • 18.9.1 COMPANY SNAPSHOT
    • 18.9.2 REVENUE ANALYSIS
    • 18.9.3 PRODUCT PORTFOLIO
    • 18.9.4 RECENT DEVELOPMENTS
  • 18.10 JASPER THERAPEUTICS, INC.
    • 18.10.1 COMPANY SNAPSHOT
    • 18.10.2 PRODUCT PORTFOLIO
    • 18.10.3 RECENT DEVELOPMENT
  • 18.11 JCR PHARMACEUTICALS CO., LTD.
    • 18.11.1 COMPANY SNAPSHOT
    • 18.11.2 REVENUE ANALYSIS
    • 18.11.3 PRODUCT PORTFOLIO
    • 18.11.4 RECENT DEVELOPMENTS
  • 18.12 JOHNSON & JOHNSONS SERVICES, INC.
    • 18.12.1 COMPANY SNAPSHOT
    • 18.12.2 REVENUE ANALYSIS
    • 18.12.3 PRODUCT PORTFOLIO
    • 18.12.4 RECENT DEVELOPMENTS
  • 18.13 MEDTRONIC
    • 18.13.1 COMPANY SNAPSHOT
    • 18.13.2 REVENUE ANALYSIS
    • 18.13.3 PRODUCT PORTFOLIO
    • 18.13.4 RECENT DEVELOPMENTS
  • 18.14 NOVARTIS AG
    • 18.14.1 COMPANY SNAPSHOT
    • 18.14.2 REVENUE ANALYSIS
    • 18.14.3 PRODUCT PORTFOLIO
    • 18.14.4 RECENT DEVELOPMENTS
  • 18.15 ON-X LIFE TECHNOLOGIES (A SUBSIDIARY OF CRYOLIFE, INC.)
    • 18.15.1 COMPANY SNAPSHOT
    • 18.15.2 REVENUE ANALYSIS
    • 18.15.3 PRODUCT PORTFOLIO
    • 18.15.4 RECENT DEVELOPMENTS
  • 18.16 PFIZER INC.
    • 18.16.1 COMPANY SNAPSHOT
    • 18.16.2 REVENUE ANALYSIS
    • 18.16.3 PRODUCT PORTFOLIO
    • 18.16.4 RECENT DEVELOPMENTS
  • 18.17 REGENXBIO INC.
    • 18.17.1 COMPANY SNAPSHOT
    • 18.17.2 REVENUE ANALYSIS
    • 18.17.3 PRODUCT PORTFOLIO
    • 18.17.4 RECENT DEVELOPMENTS
  • 18.18 SANGAMO THERAPEUTICS
    • 18.18.1 COMPANY SNAPSHOT
    • 18.18.2 REVENUE ANALYSIS
    • 18.18.3 PRODUCT PORTFOLIO
    • 18.18.4 RECENT DEVELOPMENT
  • 18.19 STRYKER
    • 18.19.1 COMPANY SNAPSHOT
    • 18.19.2 REVENUE ANALYSIS
    • 18.19.3 PRODUCT PORTFOLIO
    • 18.19.4 RECENT DEVELOPMENTS
  • 18.20 UCB S.A.
    • 18.20.1 COMPANY SNAPSHOT
    • 18.20.2 REVENUE ANALYSIS
    • 18.20.3 PRODUCT PORTFOLIO
    • 18.20.4 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS